Overview:

Summary

GlobalData, the industry analysis specialist, has released its new report, “Premature Ejaculation (PE) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Premature Ejaculation Therapeutics market. The report identifies the key trends shaping and driving the global Premature Ejaculation Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Premature Ejaculation Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Premature Ejaculation Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Premature Ejaculation Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Premature Ejaculation Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Premature Ejaculation Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Premature Ejaculation Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Premature Ejaculation Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Premature Ejaculation Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Premature Ejaculation Therapeutics market landscape? – Identify, understand and capitalize."

Companies Mentioned

Shionogi & Co.
Vectura Group plc
GlaxoSmithKline
Dong-A Pharmaceutical Co., Ltd.

1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Premature Ejaculation Therapeutics: Introduction 6
2.1 Disease Overview 6
2.2 Etiology and Pathophysiology 7
2.3 Signs and Symptoms 8
2.4 Diagnosis and Epidemiology 8
2.5 Treatment and Management Options 8
2.6 Referral Pathways 10
2.7 GlobalData Pipeline Report Guidance 11
3 PE Therapeutics: Market Characterization 12
3.1 PE Therapeutics Market Size (2005–2010) – Global 12
3.2 PE Therapeutics Market Forecast (2010-2017) – Global 13
3.3 PE Therapeutics Market Size (2005-2010) – The US 14
3.4 PE Therapeutics Market Forecast (2010-2017) – The US 15
3.5 PE Therapeutics Market Size (2005-2010) – France 16
3.6 PE Therapeutics Market Forecast (2010-2017) – France 17
3.7 PE Therapeutics Market Size (2005-2010) – Germany 18
3.8 PE Therapeutics Market Forecast (2010-2017) – Germany 19
3.9 PE Therapeutics Market Size (2005-2010) – Italy 20
3.10 PE Therapeutics Market Forecast (2010-2017) – Italy 21
3.11 PE Therapeutics Market Size (2005-2010) – Spain 22
3.12 PE Therapeutics Market Forecast (2010-2017) – Spain 23
3.13 PE Therapeutics Market Size (2005-2010) – The UK 24
3.14 PE Therapeutics Market Forecast (2010-2017) – The UK 25
3.15 PE Therapeutics Market Size (2005-2010) – Japan 26
3.16 PE Therapeutics Market Forecast (2010-2017) – Japan 27
3.17 Driver and Barriers for the PE Therapeutics Market 28
3.17.1 Drivers for the PE Therapeutics Market 28
3.17.2 Barriers for the PE Therapeutics Market 28
3.18 Opportunity and Unmet Need Analysis 29
3.19 Key Takeaway 29
4 PE Therapeutics: Competitive Assessment 30
4.1 Overview 30
4.2 Strategic Competitor Assessment 30
4.3 Product Profiles for the Major Marketed Products in the PE Therapeutics Market 31
4.3.1 Priligy (dapoxetine) 31
4.3.2 SSRIs (Selective Serotonin Reuptake Inhibitors) 32
4.4 Key Takeaway 34
5 PE Therapeutics: Pipeline Assessment 35
5.1 Overview 35
5.2 Strategic Pipeline Assessment 35
5.3 PE Therapeutics Pipeline – Pipeline by Phases of Development 35
5.3.1 PE Therapeutics – Phase III Pipeline 35
5.3.2 PE Therapeutics – Phase II Pipeline 36
5.3.3 PE Therapeutics – Phase I Pipeline 36
5.3.4 PE Therapeutics Market – Discovery and Pre-Clinical Pipeline 36
5.3.5 Technology Trends Analytic Framework 37
5.4 PE Therapeutics Market – Clinical Pipeline by Mechanism of Action 39
5.5 PE Therapeutics – Promising Drugs under Clinical Development 39
5.6 Molecule Profile for Promising Drugs under Clinical Development 40
5.6.1 PSD502/TEMPE 40
5.7 Key Takeaway 40
6 PE Therapeutics: Clinical Trials Mapping 41
6.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 41
6.2 Clinical Trials by Phase 42
6.3 Clinical Trials by Trial Status 43
6.4 Prominent Sponsors 44
6.5 Top Companies Participating in PE Therapeutics Clinical Trials 45
7 Strategic Assessment 46
7.1 Key Events Impacting the Future Market 46
7.2 PE Therapeutics: Implications for Future Market Competition 47
8 PE Therapeutics: Future Players 48
8.1 Introduction 48
8.2 Company Profiles 48
8.2.1 Shionogi & Co. 48
8.2.2 Vectura Group plc 51
8.2.3 GlaxoSmithKline 52
8.2.4 Dong-A Pharmaceutical Co., Ltd. 57
8.2.5 Other Companies in the PE Therapeutics Market 59
9 PE Therapeutics: Licensing and Partnership Deals 60
10 PE Therapeutics: Appendix 61
10.1 Market Definitions 61
10.2 Abbreviations 61
10.3 Research Methodology 62
10.3.1 Coverage 62
10.3.2 Secondary Research 62
10.3.3 Forecasting 63
10.3.4 Primary Research 65
10.3.5 Expert Panel Validation 66
10.4 Contact Us 66
10.5 Disclaimer 66
10.6 Bibliography 66"

1.1 List of Tables
Table 1: PE Definitions by Different Authorities 6
Table 2: Medical Therapy Options for the Treatment of PE 9
Table 3: PE Therapeutics Market, Global, Revenue ($m), 2005–2010 12
Table 4: PE Therapeutics Market, Global, Forecast ($m), 2010–2017 13
Table 5: PE Therapeutics Market, The US, Revenue ($m), 2005–2010 14
Table 6: PE Therapeutics Market, The US, Forecasts ($m), 2010–2017 15
Table 7: PE Therapeutics Market, France, Revenue ($m), 2005–2010 16
Table 8: PE Therapeutics Market, France, Forecasts ($m), 2010–2017 17
Table 9: PE Therapeutics Market, Germany, Revenue ($m), 2005–2010 18
Table 10: PE Therapeutics Market, Germany, Forecasts ($m), 2010–2017 19
Table 11: PE Therapeutics Market, Italy, Revenue ($m), 2005–2010 20
Table 12: PE Therapeutics Market, Italy, Forecasts ($m), 2010–2017 21
Table 13: PE Therapeutics Market, Spain, Revenue ($m), 2005–2010 22
Table 14: PE Therapeutics Market, Spain, Forecasts ($m), 2010–2017 23
Table 15: PE Therapeutics Market, The UK, Revenue ($m), 2005–2010 24
Table 16: PE Therapeutics Market, The UK, Forecasts ($m), 2010–2017 25
Table 17: PE Therapeutics Market, Japan, Revenue ($m), 2005–2010 26
Table 18: PE Therapeutics Market, Japan, Forecasts ($m), 2010–2017 27
Table 19: Priligy Clinical Trial Details 32
Table 20: Zoloft Clinical Trial Details 33
Table 21: Prozac Clinical Trial Details 34
Table 22: PE Therapeutics, Phase III Pipeline, 2011 35
Table 23: PE Therapeutics, Phase II Pipeline, 2011 36
Table 24: PE Therapeutics, Phase I Pipeline, 2011 36
Table 25: PE Therapeutics, Pre-Clinical and Discovery Pipeline, 2011 36
Table 26: PE Therapeutics, Most Promising Drugs Under Clinical Development, 2011 39
Table 27: PE Therapeutics, Clinical Trials by Country, 2011 41
Table 28: PE Therapeutics, Clinical Trials by Phase, 2011 42
Table 29: PE Therapeutics, Number of Clinical Trials by Status, 2011 43
Table 30: PE Therapeutics, Prominent Sponsors by Number of Trials, 2011 45
Table 31: PE Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 45
Table 32: Shionogi & Co., Male Health Pipeline, 2011 49
Table 33: Shionogi & Co., Deals, 2009-2011 50
Table 34: Vectura Group plc, Male Health Pipeline, 2011 51
Table 35: Vectura Group plc, Deals, 2009-2011 52
Table 36: GlaxoSmithKline, Male Health Pipeline, 2011 53
Table 37: GlaxoSmithKline Plc., Deals, Alliances and Partnerships , 2009-2011 54
Table 38: Dong-A Pharmaceuticals, Male Health Pipeline Products, 2011 58
Table 39: Dong-A Pharmaceuticals, Deals, 2009-2011 58
Table 40: PE Therapeutics Market, Future Players, 2011 59
Table 41: PE Therapeutics, Global, Deals, 2009-2011 60"

1.2 List of Figures
Figure 1: Management Algorithm of  PE 9
Figure 2: Referral Pathways 10
Figure 3: PE Therapeutics Market, Global, Revenue ($m), 2005–2010 12
Figure 4: PE Therapeutics Market, Global, Forecast ($m), 2010–2017 13
Figure 5: PE Therapeutics Market, The US, Revenue ($m), 2005–2010 14
Figure 6: PE Therapeutics Market, The US, Forecast ($m), 2010–2017 15
Figure 7: PE Therapeutics Market, France, Revenue ($m), 2005–2010 16
Figure 8: PE Therapeutics Market, France, Forecast ($m), 2010–2017 17
Figure 9: PE Therapeutics Market, Germany , Revenue ($m), 2005–2010 18
Figure 10: PE Therapeutics Market, Germany , Forecast ($m), 2010–2017 19
Figure 11: PE Therapeutics Market, Italy, Revenue ($m), 2005–2010 20
Figure 12: PE Therapeutics Market, Italy, Forecast ($m), 2010–2017 21
Figure 13: PE Therapeutics Market, Spain, Revenue ($m), 2005–2010 22
Figure 14: PE Therapeutics Market, Spain, Forecast ($m), 2010–2017 23
Figure 15: PE Therapeutics Market, The UK, Revenue ($m), 2005–2010 24
Figure 16: PE Therapeutics Market, The UK, Forecast ($m), 2010–2017 25
Figure 17: PE Therapeutics Market, Japan, Revenue ($m), 2005–2010 26
Figure 18: PE Therapeutics Market, Japan, Forecast ($m), 2010–2017 27
Figure 19: Opportunity and Unmet Need in the PE Therapeutics Market, 2010 29
Figure 20: PE Therapeutics Market, Strategic Competitor Assessment, 2011 30
Figure 21: PE Therapeutics, Pipeline by Phase of Development (%), 2011 35
Figure 22: PE Therapeutics, Technology Trends Analytics Framework, 2011 37
Figure 23: PE Therapeutics, Technology Trends Analytics Framework, Description, 2011 38
Figure 24: PE Therapeutics, Pipeline by Mechanism of Action (%), 2011 39
Figure 25: PE Therapeutics, Clinical Trials by Country, 2011 41
Figure 26: PE Therapeutics, Clinical Trials by Phase (%), 2011 42
Figure 27: PE Therapeutics, Clinical Trials by Status (%), 2011 43
Figure 28: PE Therapeutics, Overall Sponsors (%), 2011 44
Figure 29: PE Therapeutics, Prominent Sponsors (%), 2011 44
Figure 30: PE Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 45
Figure 31: PE Therapeutics Market, Drivers and Restraints 2011 46
Figure 32: Implications for Future Market Competition in the PE Market, 2011 47
Figure 33: PE Therapeutics Market, Pipeline by Company, 2011 48
Figure 34: GlobalData Market Forecasting Model 65